Melanoma Therapeutic Market

Melanoma Therapeutic Market by Drugs (Yervoy, Keytruda, Zelboraf, Generics, Imlygic, Cotellic, Opdivo, and Mekinist+Tafinlar), Therapies (Immunotherapy, Radiation Therapy, Targeted Therapy, and Chemotherapy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2212
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 43
  • No. Of Pages: 183
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global melanoma therapeutic market size is estimated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the huge investment on safety and efficacy of melanoma therapy and increasing demand for advanced technology for the better treatment procedure in the market.

Melanoma Therapeutic Market key takeaways

Melanoma is one of the skin cancers that develops when pigment-producing cells become cancerous due to mutation. Pigmented cells can be found in the skin and other parts of the body, such as intestine and the eyes. Melanoma is not much common as squamous and basal cell skin cancers. On the other hand, unrepaired DNA damage develops this type of cancer to skin cells and is likely to spread all over the body. Exposure to UV light from the sun and tanning lamps causes melanoma.

As per the World Health Organization (WHO) report, more than two million people have been found with non-melanoma skin cancer and nearly 132,000 people with melanoma. According to the American Cancer Society (ACS), approximately 96,480 new instances of melanoma were reported in 2019, out of which 7,230 people died from the disease. The COVID-19 pandemic has resulted in unforeseen consequences such as significant delays in disease detection and treatment. On the other hand, hospitals and healthcare services were drastically curtailed owing to quarantine and social distancing precautions imposed by governments across the globe. In addition, the COVID-19 pandemic had a significant impact on the functioning of hospital treatment for non-COVID-19 patients in hospitals.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing incidence of skin allergies, skin cancer, and melanoma is one of the key driving factors of the market growth.
  • Ongoing awareness campaigns conducted by governments and private organizations to spread knowledge about cancer treatment is expected to upsurge the growth of the market.
  • Rising number of approvals & licensing provided by regulatory bodies for novel therapeutics is another major factor to fuel the market growth during the forecast period.
  • High cost involved in treatment procedures is expected to hinder the market in coming years.
  • Healthy market competition and geographical expansion by key industry leaders in therapeutics market are expected to offer great opportunity for market growth during the forecast period.

Scope of the Report

The report on the global melanoma therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Melanoma Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs (Yervoy, Keytruda, Zelboraf, Generics, Imlygic, Cotellic, Opdivo, and Mekinist+Tafinlar), and Therapies (Immunotherapy, Radiation Therapy, Targeted Therapy, and Chemotherapy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

AB Sciences; Bristol-Myers Squibb Co.; AstraZeneca; Amgen, Inc.; Merck & Co.; F. Hoffmann-La Roche Ltd.; Novartis AG; and Daiichi Sankyo Co. Ltd.

 

Market Segment Insights

Generic segment is estimated to register a substantial CAGR

Based on drugs, the global melanoma therapeutics market is segregated as yervoy, keytruda, zelboraf, generics, imlygic, cotellic, opdivo, and mekinist + tafinlar. The generic segment is estimated to register a substantial CAGR during the forecast period. The segment growth is attributed the ease in product development, cost-effectiveness, and early approvals provided by regulatory bodies as compared to biologics.

On the other hand, due to the patent expiration of established brands such as yervoy and imlygic, they are gradually losing their market share during the forecast period. Imlygic's patent protection is expected to expire in 2021, resulting in lower revenue for Amgen, Inc. Similarly, Yervoy's patent exclusivity in the United States is set to expire in 2022 and in Europe in 2020.

Melanoma Therapeutic Market by drugs

Immunotherapy segment is projected to expand at a considerable CAGR

On the basis of therapies, the market is segmented into immunotherapy, radiation therapy, targeted therapy, and chemotherapy. The immunotherapy segment is projected to expand at a considerable CAGR during the forecast period owing to the higher success rate in the treatment of the cancer cell effectively. There are various immunotherapy alternatives available for the treatment of melanoma that are FDA-approved. Additionally, technologically advanced & improved treatment of melanoma with immunotherapy medications has been performed, which is known as checkpoint inhibitors. Thus, the immunotherapy segment is projected to boost by the strong emerging pipeline for melanoma treatment during the forecast period.

North America is anticipated to constitute a key market share

In terms of regions, the global melanoma therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the improving healthcare infrastructure and strong product in the pipeline in the region. According to the Skin Cancer Foundation, one out of every five Americans is suffering from skin cancer disease during their lifetime. In addition, as per the American Cancer Society report, there were around 91,270 new instances of melanoma was diagnosed in the United States in 2018. In order to meet patient needs, the US government has adopted favorable reimbursement policies for the treatment of various disorders. It is expected to boost the North America market during the forecast period.

Melanoma Therapeutic Market by Regions

Segments

Segments Covered in the Report
The global melanoma therapeutics market has been segmented on the basis of

Drugs

  • Yervoy
  • Keytruda
  • Zelboraf
  • Generics
  • Imlygic
  • Cotellic
  • Opdivo
  • Mekinist+Tafinlar

Therapies

  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • AB Sciences
  • Bristol-Myers Squibb Co.
  • AstraZeneca
  • Amgen, Inc.
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Daiichi Sankyo Co. Ltd.

Competitive Landscape

Some of the major players competing in the market are AB Sciences; Bristol-Myers Squibb Co.; AstraZeneca; Amgen, Inc.; Merck & Co.; F. Hoffmann-La Roche Ltd.; Novartis AG; and Daiichi Sankyo Co. Ltd.

These key players are highly competitive in nature and have engaged in several marketing strategies such as partnerships, expansion, merger & acquisition, R&D, and new product launches in order to gain larger revenue share in the market. For example, in July 2016, Bristol-Myers Squibb Co. has acquired Cormorant Pharmaceuticals to expand its immuno-oncology pipeline in the market.

Melanoma Therapeutic Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Melanoma Therapeutic Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Melanoma Therapeutic Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Melanoma Therapeutic Market - Supply Chain
  4.5. Global Melanoma Therapeutic Market Forecast
     4.5.1. Melanoma Therapeutic Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Melanoma Therapeutic Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Melanoma Therapeutic Market Absolute $ Opportunity
5. Global Melanoma Therapeutic Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Melanoma Therapeutic Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Melanoma Therapeutic Demand Share Forecast, 2019-2026
6. North America Melanoma Therapeutic Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Melanoma Therapeutic Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Melanoma Therapeutic Demand Share Forecast, 2019-2026
7. Latin America Melanoma Therapeutic Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Melanoma Therapeutic Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Melanoma Therapeutic Demand Share Forecast, 2019-2026
8. Europe Melanoma Therapeutic Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Melanoma Therapeutic Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Melanoma Therapeutic Demand Share Forecast, 2019-2026
9. Asia Pacific Melanoma Therapeutic Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Melanoma Therapeutic Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Melanoma Therapeutic Demand Share Forecast, 2019-2026
10. Middle East & Africa Melanoma Therapeutic Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Melanoma Therapeutic Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Melanoma Therapeutic Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Melanoma Therapeutic Market: Market Share Analysis
  11.2. Melanoma Therapeutic Distributors and Customers
  11.3. Melanoma Therapeutic Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. AB Sciences
     11.4.2. Bristol-Myers Squibb Co.
     11.4.3. AstraZeneca
     11.4.4. Amgen, Inc.
     11.4.5. Merck & Co.
     11.4.6. F. Hoffmann-La Roche Ltd.
     11.4.7. Novartis AG
     11.4.8. Daiichi Sankyo Co.

Segments Covered in the Report
The global melanoma therapeutics market has been segmented on the basis of

Drugs

  • Yervoy
  • Keytruda
  • Zelboraf
  • Generics
  • Imlygic
  • Cotellic
  • Opdivo
  • Mekinist+Tafinlar

Therapies

  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • AB Sciences
  • Bristol-Myers Squibb Co.
  • AstraZeneca
  • Amgen, Inc.
  • Merck & Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Daiichi Sankyo Co. Ltd.

Some of the major players competing in the market are AB Sciences; Bristol-Myers Squibb Co.; AstraZeneca; Amgen, Inc.; Merck & Co.; F. Hoffmann-La Roche Ltd.; Novartis AG; and Daiichi Sankyo Co. Ltd.

These key players are highly competitive in nature and have engaged in several marketing strategies such as partnerships, expansion, merger & acquisition, R&D, and new product launches in order to gain larger revenue share in the market. For example, in July 2016, Bristol-Myers Squibb Co. has acquired Cormorant Pharmaceuticals to expand its immuno-oncology pipeline in the market.

Melanoma Therapeutic Market by key players

Buy Report